Evidence map›Paper›PMID 40117520›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2025

Single-Cell Transcriptomics Identifies a Prominent Role for the MIF-CD74 Axis in Myasthenia Gravis Thymus.

Paula Terroba-Navajas, I-Na Lu, Isaak Quast, Michael Heming, Christian W Keller, Lennard Ostendorf, Anja Erika Hauser, Ronja Mothes, Helena Radbruch, Frauke Stascheit and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Paula Terroba-NavajasDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.
I-Na LuDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.ORCID 0000-0002-3845-7386
Isaak QuastDepartment of Immunology, Monash University, Melbourne, VIC, Australia.ORCID 0000-0001-6517-8537
Michael HemingDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.ORCID 0000-0002-9568-2790
Christian W KellerDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.ORCID 0000-0003-2276-0003
Lennard OstendorfDepartment of Nephrology and Medical Intensive Care, Charite Universitatsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.ORCID 0000-0003-3553-6406
Anja Erika HauserDepartment of Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.ORCID 0000-0002-7725-9526
Ronja MothesDeutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.
Helena RadbruchDepartment of Neuropathology, Charite Universitatsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.ORCID 0000-0001-6941-3397
Frauke StascheitDepartment of Neurology with Experimental Neurology, Neuroscience Clinical Resarch Center, Charite Universitatsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; and.ORCID 0000-0001-5306-7880
Andreas Georg Otto MeiselDepartment of Neurology with Experimental Neurology, Neuroscience Clinical Resarch Center, Charite Universitatsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; and.ORCID 0000-0001-7233-5342
Heinz WiendlDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.ORCID 0000-0003-4310-3432
Gerd Meyer Zu HörsteDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.ORCID 0000-0002-4341-4719
Nick WillcoxDepartments of Clinical Neurosciences, Royal Free Hospital, London Until 1988, Then Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom.ORCID 0000-0003-2380-7686
Jan D LünemannDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.ORCID 0000-0002-3007-708X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesMyasthenia gravis (MG) is an autoimmune disease most frequently caused by autoantibodies (auto-Abs) against the acetylcholine receptor (AChR) located at the neuromuscular junction. Thymic follicular hyperplasia is present in most of the patients with early-onset AChR-Ab

methodsWe constructed a single cell-based transcriptional profile of lymphoid cell types in thymi from 11 immunotherapy-naïve patients with EOMG. Multiplex histology and ELISA were used to determine migration inhibitory factor (MIF) levels.

resultsWithin EOMG thymi, we consistently observed 6 distinct clusters of B-cell populations maturing toward germinal center (GC)-associated and Ab-secreting cells, featuring prominent GC activity, as indicated by substantial clonal expansions and cycling B-cell subsets. Cell-cell interactome predictions identified strong interactions between T cells and GC-associated and memory B cells, dominated by B-cell prosurvival signaling through the MIF-CD74 axis. Multiplex histology confirmed abundant expression of CD74 in MG thymic B cells. Circulating MIF levels in EOMG correlated with higher disease severity as assessed by Myasthenia Gravis Foundation of America status. DISCUSSION: Our data not only illustrate and define hyperplastic thymic niches in MG as favorable environments for pathogenic B-cell proliferation, maturation, and persistence but also suggest that the MIF-CD74 axis should be investigated for potential novel therapeutic targeting in EOMG.

Indexed as

Antigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMyasthenia GravisThymus GlandTranscriptomeAdolescentAdultB-LymphocytesFemaleHumansMaleMiddle AgedSingle-Cell AnalysisYoung AdultAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIIntramolecular Oxidoreductasesinvariant chainMacrophage Migration-Inhibitory FactorsMIF protein, human

Identifiers

PMID40117520
PMCPMC11978437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.